Valuation: NetraMark Holdings Inc.

Market Cap 85.33M 60.35M 52.79M 48.69M 44.97M 5.76B 86.76M 582M 228M 2.84B 227M 222M 9.75B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 85.33M 60.35M 52.79M 48.69M 44.97M 5.76B 86.76M 582M 228M 2.84B 227M 222M 9.75B EV / Sales 2026 *
213x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
07-09 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
07-09 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
06-29 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
06-29 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
05-14 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
05-07 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
05-04 NetraMark Holdings Inc. Announces Executive Changes CI
04-22 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
04-20 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
04-09 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
03-25 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
03-25 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
03-25 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
Manager TitleAgeSince
Chief Executive Officer - 16/02/2022
President - 03/07/2022
Director of Finance/CFO 57 17/07/2022
Director TitleAgeSince
Chairman 40 08/06/2025
Director/Board Member - -
Director/Board Member - 15/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 60.35M
+0.19%-1.38%-23.49%+15.83% 2,861B
-1.74%-1.94%-10.77%+668.89% 304B
-8.80%+3.47%+276.55%+891.92% 130B
-0.46%+2.96%+19.83%+65.68% 106B
-4.26%-1.08%+87.48%+145.32% 91.67B
+0.48%+1.91%-20.34%+1.55% 85.3B
+1.86%+7.59%-25.04%+88.02% 68.07B
-1.18%-4.62%+3.97%+61.33% 45.15B
-1.91%-0.11%-47.63%+26.83% 39.63B
Average -1.58%+0.79%+28.95%+218.38% 414.46B
Weighted average by Cap. -0.41%-0.93%-7.94%+105.77%

Financials

2026 *2027 *
Net sales 401K 284K 248K 229K 211K 27.04M 408K 2.73M 1.07M 13.32M 1.06M 1.04M 45.8M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise